Advertisement

CNS Drugs

, Volume 20, Issue 8, pp 611–621 | Cite as

Current Issues in the Treatment of Acute Posterior Circulation Stroke

Current Opinion

Abstract

This article presents a narrative review of the non-medical, medical and endovascular aspects of the management of acute ischaemic stroke in the posterior circulation, a potentially devastating condition with high mortality and substantial disability in many of those who survive.

Optimal management requires a combination of supportive measures and specific interventions and is best delivered within a high-dependency or intensive care environment. Non-medical measures include management of physiological parameters, respiratory support where necessary and prompt treatment of complications such as the development of hydrocephalus. Deterioration in conscious state and progression of symptoms may occur some time after initial presentation and after admission to hospital; when such progression is detected, very rapid therapeutic reperfusion may be feasible. Reperfusion strategies include intravenous and intra-arterial thrombolysis (IAT) and mechanical methods to aid reperfusion, including the use of mechanical clot disruption, clot retrieval or stenting devices.

The optimal reperfusion strategy, including considerations of whether to use intravenous or intra-arterial thrombolytic approaches, the use of bridging intravenous treatment prior to intra-arterial treatment, and the use of pharmacological or mechanical adjuncts to IAT is not known. However, it seems likely that the important determinant of therapeutic efficacy is the speed and safety with which reperfusion can be achieved. It may also be that the time available to achieve reperfusion is longer than in the anterior circulation.

Keywords

Basilar Artery Abciximab Alteplase Posterior Circulation Vertebral Artery Dissection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The author was a medical co-ordinator of the AUST study of intra-arterial thrombolysis in posterior circulation stroke, and has received support from Boehringer Ingelheim for conference attendance.

References

  1. 1.
    Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521–6PubMedCrossRefGoogle Scholar
  2. 2.
    Glass TA, Hennessey PM, Pazdera L, et al. Outcome at 30 days in the New England Medical Center Posterior Circulation Registry. Arch Neurol 2002; 59: 369–76PubMedCrossRefGoogle Scholar
  3. 3.
    Voetsch B, Dewitt LD, Pessin MS, et al. Basilar artery occlusive disease in the New England Medical Center Posterior Circulation Registry. Arch Neurol 2004; 61: 496–504PubMedCrossRefGoogle Scholar
  4. 4.
    Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke 2006; 37: 922–8PubMedCrossRefGoogle Scholar
  5. 5.
    Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke 1998; 29(2): 529–34PubMedCrossRefGoogle Scholar
  6. 6.
    Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. Arch Neurol 2001; 58(8): 1209–12PubMedCrossRefGoogle Scholar
  7. 7.
    Krieger DW, Yenari MA. Therapeutic hypothermia for acute ischemic stroke: what do laboratory studies teach us? Stroke 2004; 35: 1482–9PubMedCrossRefGoogle Scholar
  8. 8.
    Rabinstein AA, Wijdicks EF. Outcome of survivors of acute stroke who require prolonged ventilatory assistance and tracheostomy. Cerebrovasc Dis 2004; 18: 325–31PubMedCrossRefGoogle Scholar
  9. 9.
    International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569–81CrossRefGoogle Scholar
  10. 10.
    Chen ZM. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641–9CrossRefGoogle Scholar
  11. 11.
    Bristow MS, Simon JE, Brown RA, et al. MR perfusion and diffusion in acute ischemic stroke: human gray and white matter have different thresholds for infarction. J Cereb Blood Flow Metab 2005; 25: 1280–7PubMedCrossRefGoogle Scholar
  12. 12.
    Ostrem JL, Saver JL, Alger JR, et al. Acute basilar artery occlusion: diffusion-perfusion MRI characterization of tissue salvage in patients receiving intra-arterial stroke therapies. Stroke 2004; 35: E30–4PubMedCrossRefGoogle Scholar
  13. 13.
    Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581–7CrossRefGoogle Scholar
  14. 14.
    Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019–26Google Scholar
  15. 15.
    Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Throm-blytic Therapy in Acute Ischemic Stroke Study investigators. Stroke 2000; 31: 811–6Google Scholar
  16. 16.
    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–25PubMedGoogle Scholar
  17. 17.
    Lindsberg PJ, Soinne L, Tatlisumak T, et al. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA 2004; 292: 1862–6PubMedCrossRefGoogle Scholar
  18. 18.
    Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003–11Google Scholar
  19. 19.
    Zeumer H, Hacke W, Kolmann HL, et al. Local fibrinolysis in basilar artery thrombosis [in German]. Dtsch Med Wochenschr 1982; 107: 728–31PubMedCrossRefGoogle Scholar
  20. 20.
    Hacke W, Zeumer H, Ferbert A, et al. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216–22PubMedCrossRefGoogle Scholar
  21. 21.
    Eckert B, Kucinski T, Pfeiffer G, et al. Endovascular therapy of acute vertebrobasilar occlusion: early treatment onset as the most important factor. Cerebrovasc Dis 2002; 14: 42–50PubMedCrossRefGoogle Scholar
  22. 22.
    Macleod MR, Davis SM, Mitchell PJ, et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 2005; 20: 12–7PubMedCrossRefGoogle Scholar
  23. 23.
    Arnold M, Nedeltchev K, Schroth G, et al. Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis ReferencesGoogle Scholar
  24. 24.
    Khatri P, Neff J, Broderick JP, et al. Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke 2005; 36: 2400–3PubMedCrossRefGoogle Scholar
  25. 25.
    Kim DJ, Lee BH, Kim DI, et al. Stent-assisted angioplasty of symptomatic intracranial vertebrobasilar artery stenosis: feasibility and follow-up results. AJNR Am J Neuroradiol 2005; 26: 1381–8PubMedGoogle Scholar
  26. 26.
    Eckert B, Koch C, Thomalla G, et al. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study. Stroke 2005; 36: 1160–5PubMedCrossRefGoogle Scholar
  27. 27.
    Junghans U, Seitz RJ, Wittsack HJ, et al. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/ IIIa inhibitor: report of four cases. Radiology 2001; 221: 795–801PubMedCrossRefGoogle Scholar
  28. 28.
    Mangiafico S, Cellerini M, Nencini P, et al. Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases. Stroke 2005; 36: 2154–8PubMedCrossRefGoogle Scholar
  29. 29.
    Centocor press release, 28 October 2005. Patient enrolment permanently discontinued in investigational clinical trial of Reopro© (abciximab) for acute ischemic stroke [online]. Available from URL: http://www.centocor.com/news/news_103105.jsp [Accessed 2006 May 30]
  30. 30.
    Berlis A, Lutsep H, Barnwell S, et al. Mechanical thrombolysis in acute ischemic stroke with endovascular photoacoustic recanalization. Stroke 2004; 35: 1112–6PubMedCrossRefGoogle Scholar
  31. 31.
    Chopko BW, Kerber C, Wong W, et al. Transcatheter snare removal of acute middle cerebral artery thromboembolism: technical case report. Neurosurgery 2000; 46: 1529–31PubMedCrossRefGoogle Scholar
  32. 32.
    Bellon RJ, Putman CM, Budzik RF, et al. Rheolytic thrombectomy of the occluded internal carotid artery in the setting of acute ischemic stroke. AJNR Am J Neuroradiol 2001; 22: 526–30PubMedGoogle Scholar
  33. 33.
    Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1: a phase 1 study of mechanical embolus removal in cerebral ischemia. Stroke 2004; 35: 2848–54PubMedCrossRefGoogle Scholar
  34. 34.
    Yu W, Binder D, Foster-Barber A, et al. Endovascular embolectomy of acute basilar artery occlusion. Neurology 2003; 61: 1421–3PubMedCrossRefGoogle Scholar
  35. 35.
    Nedeltchev K, Remonda L, Do DD, et al. Acute stenting and thromboaspiration in basilar artery occlusions due to embolism from the dominating vertebral artery. Neuroradiology 2004; 46: 686–91PubMedCrossRefGoogle Scholar
  36. 36.
    Favrole P, Saint-Maurice JP, Bousser MG, et al. Use of mechanical extraction devices in basilar artery occlusion. J Neurol Neurosurg Psychiatry 2005; 76: 1462–4PubMedCrossRefGoogle Scholar
  37. 37.
    Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 1432–8PubMedCrossRefGoogle Scholar
  38. 38.
    The IMS II Investigators. Preliminary results of IMS II Trial [abstract no. 501]. International Stroke Conference; 2006 Feb 16–18; Kissimmee (FL). Dallas (TX): American Stroke Association, 2006Google Scholar
  39. 39.
    Broderick JP. The IMS III trial: a comparison of a combined IV/ IA approach to recanalization with standard IV rt-PA within 3 hours of onset [abstract no. 21.4]. International Stroke Conference; 2006 Feb 16–18; Kissimmee (FL). Dallas (TX): American Stroke Association, 2006Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Department of NeurologyStirling Royal InfirmaryStirlingUK
  2. 2.Division of Clinical NeurosciencesUniversity of Edinburgh, Western General HospitalEdinburghUK

Personalised recommendations